Ensysce Biosciences (ENSC) Revenue (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Revenue of $493104.0 for Q3 2025, down 85.58% year-over-year from $3.4 million in Q3 2024, and down 64.04% quarter-over-quarter from $1.4 million in Q2 2025.
Ensysce Biosciences (ENSC) Revenue (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Revenue for 6 consecutive years, with $493104.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Revenue fell 85.58% year-over-year to $493104.0; the TTM figure through Sep 2025 stood at $4.5 million (up 1.51% YoY), while the FY2024 annual figure was $5.2 million, up 133.58% from the prior year.
- Revenue retreated to $493104.0 in Q3 2025 per ENSC's latest filing, from $1.4 million in the prior quarter.
- Across five years, Revenue topped out at $3.4 million in Q3 2024 and bottomed at $181797.0 in Q2 2024.
- Historically, Revenue has averaged $877865.6 across 5 years, with a median of $515032.0 in 2023.
- Annual changes were most pronounced in 2024 — Revenue jumped 685.26% — and 2025, when it tumbled 85.58%.
- Ensysce Biosciences' Revenue stood at $1.6 million in 2021, then decreased by 12.34% to $1.4 million in 2022, then slumped by 64.07% to $515032.0 in 2023, then jumped by 153.12% to $1.3 million in 2024, then tumbled by 62.18% to $493104.0 in 2025.
- Business Quant data shows ENSC's Revenue at $493104.0 in Q3 2025, $1.4 million in Q2 2025, and $1.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 493,104.00 |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 181,797.00 |
| Mar 31, 2024 | 305,722.00 |
| Dec 31, 2023 | 515,032.00 |
| Sep 30, 2023 | 435,380.00 |
| Jun 30, 2023 | 490,472.00 |
| Mar 31, 2023 | 789,635.00 |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 279,351.00 |
| Jun 30, 2022 | 207,471.00 |
| Mar 31, 2022 | 603,098.00 |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 444,516.00 |
| Mar 31, 2021 | 250,576.00 |
| Dec 31, 2020 | 416,489.00 |